Cargando…
Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data
BACKGROUND: Stratification of patients with severe asthma by blood eosinophil counts predicts responders to anti-interleukin (IL)-5 (mepolizumab and reslizumab) and anti-IL-5 receptor α (benralizumab) therapies. This study characterized patients with severe asthma who could qualify for these biologi...
Autores principales: | Husereau, Don, Goodfield, Jason, Leigh, Richard, Borrelli, Richard, Cloutier, Michel, Gendron, Alain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913870/ https://www.ncbi.nlm.nih.gov/pubmed/29713354 http://dx.doi.org/10.1186/s13223-018-0241-1 |
Ejemplares similares
-
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021) -
Clinical, economic, and humanistic burden of asthma in Canada: a systematic review
por: Ismaila, Afisi S, et al.
Publicado: (2013) -
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
por: Woolley, Michael, et al.
Publicado: (2022) -
Burden of asthma with elevated blood eosinophil levels
por: Casciano, Julian, et al.
Publicado: (2016) -
The economic burden of prematurity in Canada
por: Johnston, Karissa M, et al.
Publicado: (2014)